It was written by SNEHA BHADTI and David Pritchett
Setting a list of relevant comparison machines in the protocol development stage is an important stage of a systematic literature review (SLR) process. The scope of this stage can help you identify the comparator to include the search strategy and qualification standards. Cokrain handbook for systematic review of arbitration The search strategy says, “We must maximize the sensitivity while trying for reasonable precision.” To add a specific comparator, you need to be careful. On the other hand, it can focus on SLR, increase precision, and reduce the burden of screening, but on the other hand, when the comparator is omitted from the protocol, it will introduce a risk that useful evidence will be missing.
challenge
Source’s SLR team has recently completed a global clinical SLR for certain types of high -end cancer in the first environment. The initial draft of the EMBASE search strategy was not limited by the intervention/comparator, and this initial search strategy returned more than 6,000 quotations. This number increases only after searching for another electronic database (e.g. Medline), and obtains more than 10,000 hits on the screen in the title/green stage. In terms of clients, selecting a wide range of literature to identify relatively small number of relevant studies has not been used to use time or resources efficiently.
way out
The Source SLR team introduced a specific comparator for the PICOS standard and electronic database search strategy. In addition to the emerging comparters currently under development, thorough studies have been conducted to identify the current approved competitors for the current approved customer products. This study includes five major stages, including the five major stages summarized in Table 1.
Table 1: Summary of the Comparison range Research Method
In addition to the comparator named in the electronic database search strategy, the number of quotations quotes has been reduced by about 57%in the title/green review stage. Comprehensive range scoping exercises required 6 -day analyst time, but focused on search until the title/green screening stage decreased from 40 to 17 days. Overall, the range movement saved the 17 -day analyst time.
Use the Pico of EU JC to the range
In January 2025, the European Union Joint Clinical Clinical Assessment (EU JCA) was implemented for new oncology and advanced treatment drugs. SOURCE previously posted a blog post about the meaning of the EU JCA for the clinical SLR. Given that the manufacturer is just given 100 days between pico finish and submission of documentsSLRs will often be carried out before pico integration and updated soon (JCA guidance states that search should be less than three months when submitted documents). From this point of view, the development of SLR protocols, including prudent editing of potentially related comparters over 27 EU member states, is important. A thorough range of research similar to what is described above plays an important role in this process. In some disease areas, clinical SLRs, not interventions, can be relaxed, but in other cases the SLR can be enormous.
To learn more about the SLR, contact Source Health Economics, a consulting that specializes in creating evidence, health economy and communication.
